


PHARMACEUTICAL 2022

Atea Pharmaceuticals Inc. Rank 10 of 475











Atea Pharmaceuticals Inc. Rank 10 of 475



The relative strengths and weaknesses of Atea Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atea Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 420% points. The greatest weakness of Atea Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 305%, being 581% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	772,403
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	56,883
Liabilities, Non-Current	5,932
Other Assets	466
Other Compr. Net Income	0
Other Expenses	17,400
Other Liabilities	0
Other Net Income	0
Property and Equipment	23
Research and Development	167,205
Revenues	351,580
Selling, General and Administrative Expense	45,785

Output Variable	Value in 1000 USD
Assets	772,892
Liabilities	62,815
Expenses	230,390
Stockholders Equity	710,077
Net Income	121,190
Comprehensive Net Income	121,190
Economic Capital Ratio	305%

